VYNE Therapeutics Divests Topical Minocycline Assets
13 janv. 2022 07h00 HE
|
VYNE Therapeutics Inc.
Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s...
VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event
03 janv. 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that management will participate in one-on-one investor meetings...
VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
18 nov. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at...
VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
10 nov. 2021 07h30 HE
|
VYNE Therapeutics Inc.
Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate...
Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study
04 nov. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced preclinical data from a validated animal study showing that its...
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
28 oct. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter...
Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies
26 oct. 2021 08h00 HE
|
VYNE Therapeutics Inc.
VYN201 exhibits anti-inflammatory effect in preclinical data similar to a super-potent glucocorticosteroidVYN201 appeared well-tolerated in mice, as seen through animal body weight and skin...
VYNE Therapeutics Announces Formation of Scientific Advisory Board
21 oct. 2021 08h00 HE
|
VYNE Therapeutics Inc.
Renowned Experts to Support VYNE’s Strategy of Developing Novel Treatments for Immunological and Inflammatory diseases SAB to Help Guide Clinical Development of VYNE’s BET Inhibitor Drug Candidates...
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
19 oct. 2021 08h00 HE
|
VYNE Therapeutics Inc.
Important milestone achieved as part of the Company’s new corporate strategy to develop treatments for immuno-inflammatory diseases Topline results anticipated in early Q1 2022 BRIDGEWATER,...
VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne
05 oct. 2021 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first patient has been enrolled in a Phase 3 study in...